The potential of parathyroid hormone as a therapy for osteoporosis

International Journal of Fertility and Women's Medicine

Volumn 47, Issue 3, 2002, Pages 103-115

  Rubin, Mishaela R ^a   Bilezikian, John P ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

Anabolic therapy; Anti resorptives(bone); Idiopathic osteoporosis; Menopause; Safety

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; PARATHYROID HORMONE; RISEDRONIC ACID;

BIOSYNTHESIS; BONE BIOPSY; BONE DENSITY; CATABOLISM; CLINICAL TRIAL; DOSE RESPONSE; HIP FRACTURE; HUMAN; HYPERCALCEMIA; MORPHOMETRICS; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; VERTEBRA FRACTURE; ANIMAL; BONE DEVELOPMENT; DRUG COMBINATION; DRUG EFFECT; FEMALE; HYPERPARATHYROIDISM; MALE; METABOLISM; OSTEOSARCOMA; RISK FACTOR;

ANIMAL; BONE DEVELOPMENT; BONE RESORPTION; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; HUMAN; HYPERPARATHYROIDISM; MALE; OSTEOPOROSIS; OSTEOSARCOMA; PARATHYROID HORMONES; RISK FACTORS; SUPPORT, U.S. GOV'T, P.H.S.; ANIMALS; HUMANS; PARATHYROID HORMONE;

EID: 0035987181     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Hyperparathyroidism: A common and polymorphic condition as illustrated by seventeen proven cases from one clinic
2. The pharmacology of estrogens in osteoporosis
3. Bisphosphonates: Mechanisms of action and clinical use
4. Calcitonin
5. Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial
6. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation
7. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial
8. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial
9. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
10. Anabolic actions of parathyroid hormone on bone
11. Skeletal disease in primary hyperparathyroidism
12. Characterization and evaluation of asymptomatic primary hyperparathyroidism
13. The histomorphometry of bone in primary hyperparathyroidism: Preservation of cancellous bone structure
14. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: Trabecular strut analysis
15. Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women
16. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism
17. A comparison of bone structure and turnover in postmenopausal women with osteoporosis or primary hyperparathyroidism
18. Bone histomorphometry in hypoparathyroid patients treated with vitamin D
19. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis
20. Circadian variation in ionized calcium and intact parathyroid hormone: Evidence for sex differences in calcium homeostasis
21. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: Differential effects of intermittent and continuous administration
22. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone
23. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: A single receptor stimulates intracellular accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium
24. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide
25. Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor
26. Pharmacological mechanisms of therapeutics: Parathyroid hormone
27. Dissociation of second messenger activation by parathyroid hormone fragments in osteosarcoma cells
28. PTH: Mechanism of action
29. Anabolic effects of PTH on bone
30. Effects of short-term recombinant human insulin-like growth factor 1 administration on bone turnover in osteopenic women with anorexia nervosa
31. Parathyroid hormone causes translocation of protein kinase-C from cytosol to membranes in rat osteosarcoma cells
32. Interactions of PTH and PTHrP with the PTH/PTHrP receptor and with downstream signaling pathways: Exceptions that provide the rules
33. Truncation of the amino terminus of PTH alters its anabolic activity on bone in vivo
34. Analysis of gene expression by DNA microarray reveals novel clues to the mechanism of the catabolic and anabolic actions of PTH in bone
35. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures
36. Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats
37. Parathyroid hormone
38. Parathyroid hormone stimulates release of insulin-like growth factor-I (IGF-I) and IGF-II from neonatal mouse calvaria in organ culture
39. PTH restores bone mass and enhances osteoblast IGF-I gene expression in ovariectomized rats
40. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
41. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
42. Clinical review 114: Hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases
43. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation
44. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene
45. Mechanisms of biphasic anabolic and catabolic effects of parathyroid hormone (PTH) on bone cells
46. RANK ligand stimulates anabolic bone formation
47. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
48. Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats
49. Cyclical treatment of osteopenic ovariectomized adult rats with PTH(1-34) and pamidronate
50. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys
51. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34)
52. Preliminary trial of low doses of human parathyroid hormone 1-34 peptide in treatment of osteoporosis
53. Short-term effects of synthetic human parathyroid hormone-(1-34) administration on bone mineral metabolism in osteoporotic patients
54. Anabolie effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial
55. The relationship between changes in femoral bone density and calcium balance in patients with involutional osteoporosis treated with human PTH fragment 1-34
56. Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotie patients
57. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D
58. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol
59. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis
60. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride
61. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses
62. Human parathyroid peptide treatment of vertebral osteoporosis
63. Periodic courses of human 1-34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis
64. Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38)hPTH and diphosphonate EHDP. Protocol of study I, osteoporosis trial Hannover
65. Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients
66. Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients
67. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients
68. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency
69. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): A randomized controlled trial
70. Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis
71. A randomized controlled multi-center study of 1-84hPTH for treatment of postmenopausal osteoporosis
72. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate
73. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
74. Insulin-like growth factor-I in men with idiopathic osteoporosis
75. Reduced serum levels of the growth hormone-dependent insulin-like growth factor binding protein and a negative bone balance at the level of individual remodeling units in idiopathic osteoporosis in men
76. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers
77. Changes in bone markers predict bone accrual in osteoporotic men treated with parathyroid hormone
78. Parathyroid hormone (PTH 1-34) as a treatment for idiopathic osteoporosis in men: Changes in bone mineral density, bone markers and optimal duration of therapy
79. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study
80. Brief therapy with recombinant human parathyroid hormone (1-34) increases lumbar spine bone mineral density in men with idiopathic or hypogonadal osteopenia
81. Recombinant human parathyroid hormone (1-34) therapy reduces the incidence of moderate/severe vertebral fractures in men with low bone density
82. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
83. Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal
84. Parathyroid hormone 1-34 (hPTH 1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis-results from a placebo-controlled randomized trial
85. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial
86. PTH treatment directly stimulates bone formation in cancellous and cortical bone in humans
87. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis
88. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women
89. PTH and bisphosphonates in the treatment of osteoporosis: Design of the PTH and alendronate (PaTH) trial
90. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery
91. Prediction of bone mass change after parathyroidectomy in patients with primary hyperparathyroidism
92. Primary hyperparathyroidism: Changes in trabecular bone remodeling following surgical treatment - Evaluated by histomorphometric methods
93. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial
94. The post-PTH experience in men with idiopathic osteoporosis: Bisphosphonates vs. nonpharmacologic therapy
95. Sequential parathyroid hormone/alendronate therapy for osteoporosis - Robbing Peter to pay Paul?
96. Effects of LY333334 [recombinant parathyroid hormone (1-34)] on cortical bone strength indices as assessed by peripheral quantitative computed tomography
97. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats